Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Is Dengvaxia a useful vaccine for dengue endemic areas?

Gubler DJ, Halstead SB.

BMJ. 2019 Oct 3;367:l5710. doi: 10.1136/bmj.l5710. No abstract available.

PMID:
31582375
2.

Travelling arboviruses: A historical perspective.

Halstead SB.

Travel Med Infect Dis. 2019 Sep - Oct;31:101471. doi: 10.1016/j.tmaid.2019.101471. Epub 2019 Aug 28.

PMID:
31472285
3.

Dengue infection and advances in dengue vaccines for children.

Halstead SB, Dans LF.

Lancet Child Adolesc Health. 2019 Oct;3(10):734-741. doi: 10.1016/S2352-4642(19)30205-6. Epub 2019 Aug 1. Review.

PMID:
31378686
4.

A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice.

Chan KWK, Watanabe S, Jin JY, Pompon J, Teng D, Alonso S, Vijaykrishna D, Halstead SB, Marzinek JK, Bond PJ, Burla B, Torta F, Wenk MR, Ooi EE, Vasudevan SG.

Sci Transl Med. 2019 Jun 26;11(498). pii: eaat7726. doi: 10.1126/scitranslmed.aat7726.

PMID:
31243154
5.

Japanese encephalitis vaccine for travelers: risk-benefit reconsidered.

Connor BA, Hamer DH, Kozarsky P, Jong E, Halstead SB, Keystone J, Mileno MD, Dawood R, Rogers B, Bunn WB.

J Travel Med. 2019 Jun 11;26(5). pii: taz037. doi: 10.1093/jtm/taz037. No abstract available.

PMID:
31073616
6.

NS1, Dengue's Dagger.

Halstead SB, Russell PK, Brandt WE.

J Infect Dis. 2019 Feb 19. pii: jiz083. doi: 10.1093/infdis/jiz083. [Epub ahead of print] No abstract available.

PMID:
30783665
7.

Insights from direct studies on human dengue infections.

Halstead SB.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):17-19. doi: 10.1073/pnas.1819607116. Epub 2018 Dec 13. No abstract available.

8.

Cause and consequence of loss in vaccine trust.

Dans AL, Dans LF, Silvestre MAA, Halstead SB, Guyatt GH.

Hum Vaccin Immunother. 2019;15(3):628-629. doi: 10.1080/21645515.2018.1551674. Epub 2018 Dec 11. No abstract available.

PMID:
30513242
9.

Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine.

Halstead SB.

Hum Vaccin Immunother. 2018;14(9):2158-2162. doi: 10.1080/21645515.2018.1445448. Epub 2018 May 14.

10.

Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age.

Halstead SB.

Vaccine. 2017 Nov 7;35(47):6355-6358. doi: 10.1016/j.vaccine.2017.09.089. Epub 2017 Oct 10.

PMID:
29029938
11.

Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.

Ginsburg AS, Meghani A, Halstead SB, Yaich M.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2222-2231. doi: 10.1080/21645515.2017.1356496. Epub 2017 Aug 25. Review.

12.

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Halstead SB.

Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6). pii: a030700. doi: 10.1101/cshperspect.a030700. Review.

PMID:
28716893
13.

Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue.

Halstead SB.

Lancet Infect Dis. 2017 Nov;17(11):e378-e382. doi: 10.1016/S1473-3099(17)30362-6. Epub 2017 Jul 12. Review.

PMID:
28711586
14.

A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement.

Londono-Renteria B, Troupin A, Cardenas JC, Hall A, Perez OG, Cardenas L, Hartstone-Rose A, Halstead SB, Colpitts TM.

J Gen Virol. 2017 Jul;98(7):1702-1712. doi: 10.1099/jgv.0.000833. Epub 2017 Jul 8.

PMID:
28691657
15.

Zika enhancement: a reality check.

Mahalingam S, Teixeira MM, Halstead SB.

Lancet Infect Dis. 2017 Jul;17(7):686-688. doi: 10.1016/S1473-3099(17)30340-7. Epub 2017 Jun 21. No abstract available.

PMID:
28653626
16.

Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies.

Halstead SB.

Emerg Infect Dis. 2017 Apr;23(4):569-573. doi: 10.3201/eid2304.161879. Review.

17.

Consider stopping dengvaxia administration without immunological screening.

Aguiar M, Halstead SB, Stollenwerk N.

Expert Rev Vaccines. 2017 Apr;16(4):301-302. doi: 10.1080/14760584.2017.1276831. Epub 2016 Dec 28. No abstract available.

PMID:
28010152
18.

The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.

Aguiar M, Stollenwerk N, Halstead SB.

PLoS Negl Trop Dis. 2016 Dec 21;10(12):e0005179. doi: 10.1371/journal.pntd.0005179. eCollection 2016 Dec.

19.

Is discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply.

Halstead SB, Aguiar M.

Lancet. 2016 Oct 15;388(10054):1881-1882. doi: 10.1016/S0140-6736(16)31718-4. No abstract available.

PMID:
27751396
20.

Dengue Vaccine Efficacy: Not a Zero Sum Game.

Halstead SB.

J Infect Dis. 2016 Dec 15;214(12):2014. Epub 2016 Sep 29. No abstract available.

PMID:
27694632
21.

Dengue infection.

Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB.

Nat Rev Dis Primers. 2016 Aug 18;2:16055. doi: 10.1038/nrdp.2016.55. Review.

PMID:
27534439
22.

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines.

Russell PK, Halstead SB.

PLoS Negl Trop Dis. 2016 Aug 11;10(8):e0004854. doi: 10.1371/journal.pntd.0004854. eCollection 2016 Aug. No abstract available.

23.

Critique of World Health Organization Recommendation of a Dengue Vaccine.

Halstead SB.

J Infect Dis. 2016 Dec 15;214(12):1793-1795. Epub 2016 Aug 5. No abstract available.

PMID:
27496975
24.

Dengue vaccine and the 2016 Olympics.

Halstead SB, Aguiar M.

Lancet. 2016 Jul 16;388(10041):237-8. doi: 10.1016/S0140-6736(16)31048-0. No abstract available.

PMID:
27479569
25.

The risks behind Dengvaxia recommendation.

Aguiar M, Stollenwerk N, Halstead SB.

Lancet Infect Dis. 2016 Aug;16(8):882-3. doi: 10.1016/S1473-3099(16)30168-2. No abstract available.

PMID:
27477967
26.

Response to Hadinegoro et al.

Halstead SB, Russell PK.

Vaccine. 2016 Aug 5;34(36):4275. doi: 10.1016/j.vaccine.2016.06.013. No abstract available.

PMID:
27452652
27.

Predictors of dengue severity.

Halstead SB.

J Pediatr (Rio J). 2016 Sep-Oct;92(5):429-31. doi: 10.1016/j.jped.2016.06.004. Epub 2016 Jun 28. No abstract available.

28.

Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.

Halstead SB.

Am J Trop Med Hyg. 2016 Oct 5;95(4):741-745. doi: 10.4269/ajtmh.16-0222. Epub 2016 Jun 27.

29.

Dengue vaccines: Are they safe for travelers?

Halstead SB, Aguiar M.

Travel Med Infect Dis. 2016 Jul-Aug;14(4):378-83. doi: 10.1016/j.tmaid.2016.06.005. Epub 2016 Jun 22.

PMID:
27343438
30.

Pathogenesis of Dengue: Dawn of a New Era.

Halstead SB.

F1000Res. 2015 Nov 25;4. pii: F1000 Faculty Rev-1353. doi: 10.12688/f1000research.7024.1. eCollection 2015. Review.

31.

Protective and immunological behavior of chimeric yellow fever dengue vaccine.

Halstead SB, Russell PK.

Vaccine. 2016 Mar 29;34(14):1643-7. doi: 10.1016/j.vaccine.2016.02.004. Epub 2016 Feb 10. Review.

PMID:
26873054
33.

Epidemiology of bladder stone of children: precipitating events.

Halstead SB.

Urolithiasis. 2016 Apr;44(2):101-8. doi: 10.1007/s00240-015-0835-8. Epub 2015 Nov 11. Review.

PMID:
26559057
34.

Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.

Halstead SB.

Microbiol Spectr. 2014 Dec;2(6). doi: 10.1128/microbiolspec.AID-0022-2014. Review.

PMID:
26104444
35.

Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment.

Halstead SB, Cohen SN.

Microbiol Mol Biol Rev. 2015 Sep;79(3):281-91. doi: 10.1128/MMBR.00009-15. Review.

36.

Reappearance of chikungunya, formerly called dengue, in the Americas.

Halstead SB.

Emerg Infect Dis. 2015 Apr;21(4):557-61. doi: 10.3201/eid2104.141723. Review.

37.

Economic and disease burden of dengue in Mexico.

Undurraga EA, Betancourt-Cravioto M, Ramos-Castañeda J, Martínez-Vega R, Méndez-Galván J, Gubler DJ, Guzmán MG, Halstead SB, Harris E, Kuri-Morales P, Tapia-Conyer R, Shepard DS.

PLoS Negl Trop Dis. 2015 Mar 18;9(3):e0003547. doi: 10.1371/journal.pntd.0003547. eCollection 2015 Mar.

38.

Protective immune responses to dengue virus infection and vaccines: perspectives from the field to the bench.

Halstead SB, Zompi S.

Front Immunol. 2015 Feb 18;6:75. doi: 10.3389/fimmu.2015.00075. eCollection 2015. No abstract available.

39.

Approaches to refining estimates of global burden and economics of dengue.

Shepard DS, Undurraga EA, Betancourt-Cravioto M, Guzmán MG, Halstead SB, Harris E, Mudin RN, Murray KO, Tapia-Conyer R, Gubler DJ.

PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3306. doi: 10.1371/journal.pntd.0003306. eCollection 2014 Nov. Review.

40.

Stumbles on the path to dengue control.

Halstead SB.

Lancet Infect Dis. 2014 Aug;14(8):661-662. doi: 10.1016/S1473-3099(14)70770-4. Epub 2014 May 28. No abstract available.

PMID:
24877998
41.

Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland.

Cassetti MC, Halstead SB.

Vaccine. 2014 May 30;32(26):3115-21. doi: 10.1016/j.vaccine.2014.04.017. Epub 2014 Apr 21.

PMID:
24768502
42.

Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.

Aye KS, Charngkaew K, Win N, Wai KZ, Moe K, Punyadee N, Thiemmeca S, Suttitheptumrong A, Sukpanichnant S, Prida M, Halstead SB.

Hum Pathol. 2014 Jun;45(6):1221-33. doi: 10.1016/j.humpath.2014.01.022. Epub 2014 Feb 20.

PMID:
24767772
43.

Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA.

Virology. 2014 Mar;452-453:237-46. doi: 10.1016/j.virol.2014.01.015. Epub 2014 Feb 14. Review.

44.

Identifying protective dengue vaccines: guide to mastering an empirical process.

Halstead SB.

Vaccine. 2013 Sep 23;31(41):4501-7. doi: 10.1016/j.vaccine.2013.06.079. Epub 2013 Jul 26. Review.

45.

Call to action for dengue vaccine failure.

Mahalingam S, Herring BL, Halstead SB.

Emerg Infect Dis. 2013 Aug;19(8):1335-7. doi: 10.3201/eid1908.121864. No abstract available.

46.

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.

Guzman MG, Alvarez M, Halstead SB.

Arch Virol. 2013 Jul;158(7):1445-59. doi: 10.1007/s00705-013-1645-3. Epub 2013 Mar 8. Review.

PMID:
23471635
47.

Dengue: the syndromic basis to pathogenesis research. Inutility of the 2009 WHO case definition.

Halstead SB.

Am J Trop Med Hyg. 2013 Feb;88(2):212-215. doi: 10.4269/ajtmh.12-0197. No abstract available.

48.

Dengue vascular permeability syndrome: what, no T cells?

Halstead SB.

Clin Infect Dis. 2013 Mar;56(6):900-1. doi: 10.1093/cid/cis1047. Epub 2012 Dec 14. No abstract available.

PMID:
23243186
49.

Controlling dengue with vaccines in Thailand.

Chao DL, Halstead SB, Halloran ME, Longini IM Jr.

PLoS Negl Trop Dis. 2012;6(10):e1876. doi: 10.1371/journal.pntd.0001876. Epub 2012 Oct 25.

50.

Dengue vaccine development: a 75% solution?

Halstead SB.

Lancet. 2012 Nov 3;380(9853):1535-6. doi: 10.1016/S0140-6736(12)61510-4. Epub 2012 Sep 11. No abstract available.

PMID:
22975339

Supplemental Content

Loading ...
Support Center